Analyzing Shanghai Junshi Biosciences (OTCMKTS:SHJBF) and Hyperion DeFi (NASDAQ:HYPD)

Hyperion DeFi (NASDAQ:HYPD) and Shanghai Junshi Biosciences (OTCMKTS:SHJBF) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, valuation, profitability, institutional ownership, risk and analyst recommendations.

Valuation and Earnings

This table compares Hyperion DeFi and Shanghai Junshi Biosciences”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperion DeFi	$60,000.00	443.90	-$49.82 million	($4.04)	-0.81
Shanghai Junshi Biosciences	N/A	N/A	N/A	N/A	N/A

Shanghai Junshi Biosciences has lower revenue, but higher earnings than Hyperion DeFi.

Institutional & Insider Ownership

25.8% of Hyperion DeFi shares are owned by institutional investors. 10.9% of Hyperion DeFi shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Hyperion DeFi and Shanghai Junshi Biosciences, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperion DeFi	1	2	2	0	2.20
Shanghai Junshi Biosciences	0	0	0	0	0.00

Hyperion DeFi currently has a consensus target price of $4.58, indicating a potential upside of 40.59%. Given Hyperion DeFi’s stronger consensus rating and higher probable upside, research analysts plainly believe Hyperion DeFi is more favorable than Shanghai Junshi Biosciences.

Profitability

This table compares Hyperion DeFi and Shanghai Junshi Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Hyperion DeFi	N/A	-119.59%	-68.88%
Shanghai Junshi Biosciences	N/A	N/A	N/A

Summary

Hyperion DeFi beats Shanghai Junshi Biosciences on 6 of the 8 factors compared between the two stocks.

About Hyperion DeFi

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.

About Shanghai Junshi Biosciences

Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, autoimmune, neurologic, nervous system, and infectious diseases in the People's Republic of China. The company was founded in 2012 and is headquartered in Shanghai, People's Republic of China.